ArticleInvestigative ophthalmology & visual science2025
Pax6 Directly Regulates the Raver2/sFlt-1 Expression in Corneal Epithelial Cells to Maintain the Cornea's Avascular Privilege.
Article in Investigative ophthalmology & visual science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Carrier-free targeted co-assembly of glycyrrhizin and puerarin overcomes ocular barriers for corneal alkali burn therapy via macrophage reprogramming.Materials today. Bio · 2026Article
- Transcriptomic Analysis in a Model of Aniridia-Associated Keratopathy for Target Discovery and Evaluation of Duloxetine Therapy.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to elucidate how Pax6 directly regulates Raver2 and sFlt-1 expression in corneal epithelial cells to maintain the cornea's avascular privilege during normal development. Methods: The expression levels of Pax6, Raver2, and sFlt-1 in both the mouse cornea and human corneal epithelial cell line (HCE-T) were evaluated. Changes in Raver2 and sFlt-1 expression following Pax6 knockdown were also assessed. Chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR), electrophoresis mobility shift assay (EMSA), and dual-luciferase reporter (DLR) assay were conducted to ascertain the regulatory relationship between Pax6 and Raver2. The impact on vascular endothelial cell proliferation, migration, and tube formation was examined after coculturing with siPax6-HCE-T conditioned culture medium. Additionally, corneal neovascularization (CoNV) was monitored following corneal epithelial scraping or injection of the AAV-siPax6 vector into the limbus. Results: Pax6, Raver2, and sFlt-1 were highly expressed in both HCE-T cells and normal mouse corneal epithelial layer. Interference with Pax6 expression resulted in decreased levels of Raver2 and sFlt-1 both in vivo and in vitro. TFBS1 and TFBS2 in the Raver2 promoter region were identified as potential Pax6 binding sites. ChIP-qPCR and EMSA assays confirmed the direct interaction between Pax6 and Raver2. The DLR assay demonstrated that Pax6 binding to the TFBS1 and TFBS2 regulated Raver2 expression. Vascular endothelial cell proliferation, migration, and tube formation were enhanced when cocultured with siPax6-HCE-T conditioned culture medium. CoNV progressed after corneal epithelial scraping and AAV-siPax6 vector injection. Conclusions: Pax6 directly regulates Raver2/sFlt-1 expression in corneal epithelial cells, thus preserving the cornea's avascular privilege during normal development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.